Location History:
- Ahmedabad, IN (2015)
- Gujarat, IN (2015 - 2018)
Company Filing History:
Years Active: 2015-2018
Title: Innovations by Inventor Ashok Prasad: Advancements in Pharmaceutical Patents
Introduction: Ashok Prasad, an innovative inventor based in Gujarat, India, has made significant contributions to the pharmaceutical industry with his multiple patents. With a total of eight patents to his name, he is recognized for his work in developing novel therapeutic compositions aimed at improving healthcare outcomes.
Latest Patents: Among Ashok Prasad's latest inventions is the "Amorphous form of linagliptin and process for preparation thereof." This invention focuses on an amorphous form of linagliptin, a compound used in the treatment of diabetes, and outlines the processes for preparing this form. The invention also details a pharmaceutical composition that comprises a therapeutically effective amount of the amorphous linagliptin, specifically beneficial for managing type-I and type-II diabetes, prediabetes, and glucose tolerance reduction. Additionally, he has developed "Polymorphic forms of ivabradine hydrochloride," featuring stable crystalline Form II and Form III of ivabradine hydrochloride and their respective preparation processes.
Career Highlights: Ashok Prasad is currently affiliated with Cadila Healthcare Limited, a leading healthcare company known for its research and development in pharmaceuticals. His innovative mindset and scientific expertise have enabled him to lead projects that enhance drug formulations and contribute to patient care.
Collaborations: During his career, Ashok has collaborated with notable colleagues, including Shriprakash Dhar Dwivedi and Mukul Hariprasad Sharma. These collaborations have fostered a creative environment, enabling them to innovate further in the pharmaceutical sector.
Conclusion: Ashok Prasad's contributions to pharmaceutical inventions highlight the vital role of innovation in advancing healthcare. His patents not only address current medical challenges but also pave the way for future developments in diabetes treatment and beyond.